GlassScriptPhysician profile
Abigail Guzman
NPI 1962127795
$6,628.17
in general payments reported to CMS, 2019-2025
19 companies · $2,796 in 2025
The $2,796 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $117 · 2023: $1,287 · 2024: $2,428 · 2025: $2,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,511.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,730.11 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,066.57 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $818.69 | 2023-2025 | Caplyta |
| Abbvie INC. | $615.25 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $490.40 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $405.14 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $311.09 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $289.65 | 2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $246.52 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $123.05 | 2023-2025 | Loreev Xr |
| Corium, LLC | $101.45 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $88.27 | 2024-2025 | Qelbree |
| Lundbeck LLC | $88.15 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $81.60 | 2023-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $50.77 | 2023-2024 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $47.04 | 2023-2024 | Dyanavel Xr |
| Indivior INC. | $30.12 | 2024 | Perseris |
| Axsome Therapeutics, INC. | $27.69 | 2023-2024 | Auvelity |
| Royal Biologics, INC. | $16.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.